Chiron collars PowderJect

- Last updated on GMT

Related tags: Influenza vaccine, Chiron

Chiron's has completed its acquisition of UK vaccine and drug
delivery specialist PowderJect, making it the second-largest
manufacturer of flu vaccines worldwide.

Chiron's has completed its $888 million (€782m) acquisition of UK vaccine and drug delivery specialist PowderJect, at a stroke becoming the second-largest manufacturer of influenza vaccines worldwide behind Aventis Pasteur.

The offer was declared unconditional on 7 July after Chiron acquired just under 90 per cent of PowderJect's share capital.

"By leveraging PowderJect's existing infrastructure in the US flu market, Chiron will be able to build on its platform for new products, including our portfolio of meningococcal vaccines that are in development,"​ said the US firm in a statement.

Chiron originally made overtures to PowderJect last autumn, but the UK firm rebuffed its advances on the grounds that the offer made was too low. With the takeover, Chiron gets its hands on Fluvirin, PowderJect's top-selling product, and a fast track into the US flu vaccine business.

The USA has seen significant growth in flu vaccination of late, following the US government's lowering of the threshold for free vaccination from 65 to 50. This helped Fluvirin sales surge 40 per cent to £158 million (€227m) last year.In tandem with its vaccines business, PowderJect is developing both disposable and reusable needle-free injector system for drugs that can be formulated as a powder.

Related news

Show more

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more